- The report assesses Amyloidosis therapeutics based on drug target, mechanism of action (MoA), route of
administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Amyloidosis
Reasons To Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain
competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Amyloidosis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Amyloidosis pipeline depth and focus of
Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most
attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove
them from pipeline
Buy a Sample copy of This Report @ http://www.radiantinsights.com/research/amyloidosis-pipeline-review-h22016/request-sample
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Amyloidosis Overview 10
Therapeutics Development 11
Pipeline Products for Amyloidosis - Overview 11
Pipeline Products for Amyloidosis - Comparative Analysis 12
Amyloidosis - Therapeutics under Development by Companies 13
Amyloidosis - Therapeutics under Investigation by Universities/Institutes 15
Amyloidosis - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Amyloidosis - Products under Development by Companies 19
Amyloidosis - Products under Investigation by Universities/Institutes 21
Amyloidosis - Companies Involved in Therapeutics Development 22
Alnylam Pharmaceuticals, Inc. 22
Amgen Inc. 23
Arcturus Therapeutics, Inc. 24
BELLUS Health Inc. 25
Bsim2 26
Celgene Corporation 27
GlaxoSmithKline Plc 28
Ionis Pharmaceuticals, Inc. 29
Johnson & Johnson 30
Neurimmune Holding AG 31
NeuroPhage Pharmaceuticals, Inc. 32